Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 4
2004 6
2005 14
2006 18
2007 12
2008 13
2009 12
2010 10
2011 10
2012 11
2013 18
2014 18
2015 25
2016 24
2017 29
2018 36
2019 36
2020 44
2021 52
2022 36
2023 44

Text availability

Article attribute

Article type

Publication date

Search Results

405 results

Results by year

Filters applied: . Clear all
Page 1
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro MT, Lebbè C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Gonzales Cao M, Minisini AM, De Placido S, Sanmamed MF, Mallardo D, Curvietto M, Melero I, Palmieri G, Grimaldi AM, Giannarelli D, Dummer R, Chiarion Sileni V. Ascierto PA, et al. Among authors: giannarelli d. J Clin Oncol. 2023 Jan 10;41(2):212-221. doi: 10.1200/JCO.21.02961. Epub 2022 Sep 1. J Clin Oncol. 2023. PMID: 36049147 Clinical Trial.
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, Cavalcanti E, Caracò C, Ascierto PA. Capone M, et al. Among authors: giannarelli d. J Immunother Cancer. 2018 Jul 16;6(1):74. doi: 10.1186/s40425-018-0383-1. J Immunother Cancer. 2018. PMID: 30012216 Free PMC article.
Reply by Authors.
Mastroianni R, Ferriero M, Tuderti G, Anceschi U, Bove AM, Brassetti A, Misuraca L, Zampa A, Torregiani G, Ghiani E, Giannarelli D, Guaglianone S, Gallucci M, Simone G. Mastroianni R, et al. Among authors: giannarelli d. J Urol. 2022 May;207(5):992. doi: 10.1097/JU.0000000000002422.02. Epub 2022 Feb 18. J Urol. 2022. PMID: 35176866 No abstract available.
FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
Cristinziano G, Porru M, Lamberti D, Buglioni S, Rollo F, Amoreo CA, Manni I, Giannarelli D, Cristofoletti C, Russo G, Borad MJ, Grazi GL, Diodoro MG, Giordano S, Sacconi A, Forcato M, Anastasi S, Leonetti C, Segatto O. Cristinziano G, et al. Among authors: giannarelli d. J Hepatol. 2021 Aug;75(2):351-362. doi: 10.1016/j.jhep.2021.02.032. Epub 2021 Mar 17. J Hepatol. 2021. PMID: 33741397
Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
Ruggiero CF, Fattore L, Terrenato I, Sperati F, Salvati V, Madonna G, Capone M, Valenti F, Di Martino S, Mandoj C, Liguoro D, Castaldo V, Cafaro G, Simeone E, Vanella V, Russillo M, Conti L, Cuda G, Giannarelli D, Ascierto PA, Mancini R, Ciliberto G. Ruggiero CF, et al. Among authors: giannarelli d. Theranostics. 2022 Oct 24;12(17):7420-7430. doi: 10.7150/thno.77761. eCollection 2022. Theranostics. 2022. PMID: 36438490 Free PMC article.
Open Radical Cystectomy versus Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Early Outcomes of a Single-Center Randomized Controlled Trial.
Mastroianni R, Ferriero M, Tuderti G, Anceschi U, Bove AM, Brassetti A, Misuraca L, Zampa A, Torregiani G, Ghiani E, Giannarelli D, Guaglianone S, Gallucci M, Simone G. Mastroianni R, et al. Among authors: giannarelli d. J Urol. 2022 May;207(5):982-992. doi: 10.1097/JU.0000000000002422. Epub 2022 Feb 2. J Urol. 2022. PMID: 34986007 Clinical Trial.
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.
Rossi V, Berchialla P, Giannarelli D, Nisticò C, Ferretti G, Gasparro S, Russillo M, Catania G, Vigna L, Mancusi RL, Bria E, Montemurro F, Cognetti F, Fabi A. Rossi V, et al. Among authors: giannarelli d. Cancers (Basel). 2019 Oct 26;11(11):1661. doi: 10.3390/cancers11111661. Cancers (Basel). 2019. PMID: 31717791 Free PMC article.
405 results